Hillary Clinton's campaign triggered dramatic drops in the iShares Nasdaq Biotechnology ETF (IBB) at least three times in the past 14 months causing Biotech stocks to lag the S&P 500 index by over 30%. Todd Hagopian makes the case that Biotechs have the most to gain from Donald Trump's Presidency.
Hillary Clinton's campaign triggered dramatic drops in the iShares Nasdaq Biotechnology ETF (IBB) at least three times in the past 14 months causing Biotech stocks to lag the S&P 500 index by over 30%. Todd Hagopian makes the case that Biotechs have the most to gain from Donald Trump's Presidency.
Share this Article
Recommended